Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).
Dominick Bosse, MD
Advertisement
Articles by Dominick Bosse, MD
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCCPublished: September 21st 2017 | Updated:
Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCCPublished: October 10th 2017 | Updated:
- Dr. Bosse on the Quality of Life With VEGF Plus Radium-223
Published: October 18th 2017 | Updated:
Dr. Bosse Discusses Bone-Targeted Agents in RCCPublished: March 13th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5